Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic
June 13, 2023 08:05 ET
|
Silo Pharma, Inc.
Initial indications are fibromyalgia and chronic pain ENGLEWOOD CLIFFS, NJ, June 13, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage...
Silo Pharma Announces Participation on Webull Corporate Communications Service Platform
June 02, 2023 08:50 ET
|
Silo Pharma, Inc.
Webull’s investor community can now access the SILO profile for real-time data and investor communications ENGLEWOOD CLIFFS, NJ, June 02, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:...
Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
May 30, 2023 09:00 ET
|
Silo Pharma, Inc.
Phase 2 of study will further investigate the peptides’ method, optimization, and binding affinity in human tissue ENGLEWOOD CLIFFS, NJ, May 30, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:...
Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
May 09, 2023 08:05 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, May 09, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma to Present at Psychedelic Drug Development Conference
April 24, 2023 08:15 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, April 24, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional...
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
April 19, 2023 09:00 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, April 19, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia
March 27, 2023 09:00 ET
|
Silo Pharma, Inc.
SPU-26 Pain Management Using Ketamine Composition Action supports planned IND package submission to FDA for SP-26 ENGLEWOOD CLIFFS, NJ, March 27, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc....
Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
March 15, 2023 08:40 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, March 15, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional...
Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s
February 13, 2023 08:35 ET
|
Silo Pharma, Inc.
Patent application covers use of novel homing peptides to reduce toxicity and advance payload of therapeutic ENGLEWOOD CLIFFS, NJ, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:...
Silo Pharma Announces Expansion of Intellectual Property Portfolio
February 02, 2023 08:50 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...